News Releases

  • 22 Feb 2016
    DURHAM, N.C.--(BUSINESS WIRE)--Patheon, the leading global provider of pharmaceutical development and manufacturing services today announced it has signed a strategic agreement with Grünenthal, an independent, family-owned, international research-based pharmaceutical group headquartered in Aachen, Germany, to serve as its preferred development partner for its products made using Grünenthal’s innovative abuse deterrent formulation technology INTAC®. Patheon was selected tomore...
  • 22 Feb 2016
    DURHAM, Carolina del Nord--(BUSINESS WIRE)--Patheon, fornitore di spicco di portata globale di servizi per lo sviluppo e la produzione di prodotti farmaceutici, ha annunciato quest'oggi di aver sottoscritto un accordo strategico con Grünenthal, un gruppo farmaceutico internazionale indipendente a conduzione familiare basato sulla ricerca con sede generale ad Aachen, Germania, ai sensi del quale la società fungerà da partner preferenziale per lo sviluppo dei prodotti realizzati con l'innovativamore...
  • 17 Feb 2016

    Patheon Introduces Xcelodose® Automated Encapsulator Technology at Milton Park, U.K. Facility

    Patheon, a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, has added a new filling technology that significantly reduces the time needed for formulation development and stability testing at its Milton Park, U.K., facility. The Xcelodose ® 600 S Automated Encapsulator, supports early phase development for oral dose products.This technology adds to the site’s breadth of services, from early development to life cyclemore...